| Name | Title | Contact Details |
|---|---|---|
Roberta Sanfelice |
Global HR Head - Vision Supply Chain | Profile |
Dave Turner |
Head of R&D, Contact Lens Platform | Profile |
Douglas Lilac |
Director R&D Process Development & Commercialization | Profile |
Xiao-Yu Song |
Global Head of Research & Development, Johnson & Johnson Vision | Profile |
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
UNO HEALTHCARE was established in 1996 and we provide specialty support for patients to acquire pharmaceuticals not available in their countries.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines.
AN2 Therapeutics is a biopharmaceutical company that develops therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.
Syner-G BioPharma Group is the premier solution provider of Chemistry, Manufacturing, and Controls (CMC) services for the life sciences industry. The company`s approach is based on CMC 360™, a fully integrated suite of CMC solutions that encompasses pharmaceutical development, regulatory affairs, and quality/cGxP compliance. The entire Syner-G organization is built around the premise of guiding small molecule, biologics, cell and gene therapy, and medical device innovators through the CMC process.